Search Results - "Zappacosta, Sofia"

Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C by Katzmann, Julius L., Sorio-Vilela, Francesc, Dornstauder, Eugen, Fraas, Uwe, Smieszek, Timo, Zappacosta, Sofia, Laufs, Ulrich

“…Background Many patients at very-high atherosclerotic cardiovascular disease risk do not reach guideline-recommended targets for LDL-C. There is a lack of data…”
Get full text

Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study by Yebyo, Henock G, Zappacosta, Sofia, Aschmann, Hélène E, Haile, Sarah R, Puhan, Milo A

“…We previously showed that the 10-year cardiovascular disease (CVD) risk threshold to initiate statins for primary prevention depends on the baseline CVD risk,…”
Get full text

The Patient Journey in Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD): Results From Cross-sectional Patient and Physician Surveys by Levy, Michael, Zappacosta, Sofia, Narduzzi, Silvia, Khellaf, Meheni, Unsworth, Mia, Trenholm, Emily, Paul, Friedemann

Get full text

Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study by Peto, Tunde, Akerele, Toks, Sagkriotis, Alexandros, Zappacosta, Sofia, Clemens, Andreas, Chakravarthy, Usha

“…Introduction Anti‐vascular endothelial growth factors (anti‐VEGFs) are considered standard of care therapy for diabetic macular oedema (DME). This study…”
Get full text

Association between COVID-19 and subsequent vascular events in primary care patients in Germany by Zappacosta, S., Cascarano, A., Konrad, M., Tanislav, C., Kostev, K.

“…The aim of this study was to investigate the relationship between COVID-19 diagnosis and the risk of developing a first-ever vascular event (VE) compared with…”
Get full text